Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anti-leukemia selectivity in actinomycin analogues.

F Takusagawa1, R G Carlson, R F Weaver

  • 1Department of Molecular Biosciences, University of Kansas, Lawrence 66045-7534, USA. xraymain@ku.edu

Bioorganic & Medicinal Chemistry
|April 20, 2001
PubMed
Summary

New actinomycin D analogues show potent anti-leukemia activity by selectively inhibiting RNA synthesis. Modifications at specific positions enhance efficacy against leukemia cells, offering a promising avenue for cancer therapy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Identification and bioassay of macrocyclic lactone sex pheromone of the halictine beeLasioglossum zephyrum.

Journal of chemical ecology·2013
Same author

Formic acid in caustic cephalic secretions of stingless bee,Oxytrigona (Hymenoptera: Apidae).

Journal of chemical ecology·2013
Same author

Characterization of a cDNA encoding ricin E, a hybrid ricin-Ricinus communis agglutinin gene from the castor plant Ricinus communis.

Plant molecular biology·2013
Same author

Perceived risk associated with ecstasy use: a latent class analysis approach.

Addictive behaviors·2011
Same author

Illicit use of pharmaceutical opioids among young polydrug users in Ohio.

Addictive behaviors·2009
Same author

Constructing a consensus-based prevention outcome measurement instrument.

Journal of drug education·2001

Area of Science:

  • Medicinal Chemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Actinomycin D (AMD) is a potent anticancer agent produced by microorganisms.
  • AMD's anticancer activity stems from its selective inhibition of RNA synthesis.
  • AMD's structure is well-suited for DNA binding and RNA synthesis inhibition.

Purpose of the Study:

  • To investigate the anti-leukemia activity of novel actinomycin D analogues.
  • To explore structure-activity relationships by modifying non-DNA interacting sites of AMD.
  • To identify AMD derivatives with enhanced selectivity and potency against leukemia.

Main Methods:

  • Synthesis of actinomycin D analogues with modifications at the 2,2'- and 5,5'-positions.
  • Evaluation of anti-leukemia activity through cancer cell line screening.

Related Experiment Videos

  • Assessment of RNA synthesis inhibition and DNA binding affinities.

    • Main Results:

    • Several AMD analogues demonstrated significant anti-leukemia activity.
    • Modified analogues selectively inhibited leukemia cell growth at 100- to 500-fold lower concentrations than other cancer cell lines.
    • Modifications at the 2,2'- and 5,5'-positions, involving D-amino acid and N-methyl-L-amino acid substitutions, were key.

    Conclusions:

    • Actinomycin D analogues with modifications at specific depsipeptide positions exhibit potent and selective anti-leukemia activity.
    • These findings highlight the potential of rationally designed AMD derivatives for leukemia treatment.
    • Targeted structural modifications can enhance the therapeutic index of actinomycin D.